We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
-12.38%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$12.1B
AUM Growth
-$2.55B
Cap. Flow
-$469M
Cap. Flow %
-3.86%
Top 10 Hldgs %
25.18%
Holding
858
New
52
Increased
315
Reduced
272
Closed
83

Top Buys

Rank Stock Value
1
PG icon
Procter & Gamble
PG
+$38.7M
2
AAPL icon
Apple
AAPL
+$27.7M
3
CRM icon
Salesforce
CRM
+$26.1M
4
VZ icon
Verizon
VZ
+$25.9M
5
PEP icon
PepsiCo
PEP
+$24.1M

Sector Composition

Rank Sector Weight
1 Healthcare 34.24%
2 Technology 24.24%
3 Financials 8.36%
4 Communication Services 6.82%
5 Industrials 6.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MCK icon
301
McKesson
MCK
$99.5B
$5.97M 0.05%
18,292
+2,129
+13% +$681K
NFLX icon
302
Netflix
NFLX
$293B
$5.92M 0.05%
338,700
-24,660
-7% -$547K
TRU icon
303
TransUnion
TRU
$14.9B
$5.83M 0.05%
72,902
+41,167
+130% +$3.54M
MCO icon
304
Moody's
MCO
$84.2B
$5.77M 0.05%
21,213
-9,781
-32% -$2.93M
HAS icon
305
Hasbro
HAS
$12.8B
$5.74M 0.05%
70,143
-12,814
-15% -$1.11M
GPK icon
306
Graphic Packaging
GPK
$3.3B
$5.68M 0.05%
+277,293
New +$5.85M
PCAR icon
307
PACCAR
PCAR
$70.2B
$5.63M 0.05%
102,594
-392
-0.4% -$22.1K
BSY icon
308
Bentley Systems
BSY
$10.2B
$5.59M 0.05%
+168,020
New +$6.17M
KPTI icon
309
Karyopharm Therapeutics
KPTI
$161M
$5.57M 0.05%
82,382
-6,620
-7% -$607K
FATE icon
310
Fate Therapeutics
FATE
$283M
$5.55M 0.05%
224,033
-19,407
-8% -$535K
GIS icon
311
General Mills
GIS
$19.5B
$5.47M 0.05%
72,462
-714
-1% -$50K
CCI icon
312
Crown Castle
CCI
$32.4B
$5.41M 0.04%
32,147
-97,244
-75% -$17.7M
ENTA icon
313
Enanta Pharmaceuticals
ENTA
$370M
$5.41M 0.04%
114,507
CHTR icon
314
Charter Communications
CHTR
$15.7B
$5.32M 0.04%
11,356
-1,331
-10% -$649K
PLNT icon
315
Planet Fitness
PLNT
$4.29B
$5.26M 0.04%
77,371
+8,092
+12% +$598K
RVTY icon
316
Revvity
RVTY
$12.1B
$5.16M 0.04%
36,297
+28,833
+386% +$4.32M
GMED icon
317
Globus Medical
GMED
$10.6B
$5.16M 0.04%
91,902
-17,444
-16% -$1.15M
ALB icon
318
Albemarle
ALB
$13.7B
$5.15M 0.04%
24,625
+16,339
+197% +$3.65M
FHN icon
319
First Horizon
FHN
$12.1B
$5.09M 0.04%
232,795
CIB icon
320
Grupo Cibest SA
CIB
$20.9B
$4.98M 0.04%
161,649
+156,261
+2,900% +$6.15M
WMB icon
321
Williams Companies
WMB
$86.6B
$4.97M 0.04%
159,180
+13,193
+9% +$455K
LKQ icon
322
LKQ Corp
LKQ
$6.69B
$4.94M 0.04%
100,643
+5,958
+6% +$293K
VRAY
323
DELISTED
ViewRay, Inc.
VRAY
$4.94M 0.04%
1,737,837
RAPT
324
DELISTED
RAPT Therapeutics
RAPT
$4.83M 0.04%
33,048
+13,327
+68% +$1.78M
TRV icon
325
Travelers Companies
TRV
$81.4B
$4.83M 0.04%
28,531
+2,827
+11% +$491K

Similar funds

Candriam SCA's Q2 2022 Portfolio in Review

As of Q2 2022, Candriam SCA held 858 positions worth $12.1B, down 17% from $14.7B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Candriam SCA withdrew a net $469M in Q2 2022, closing 83 positions and reducing 272 holdings. Its most notable exit was TriState Capital Holdings, Inc., an estimated $20.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 29% a quarter earlier, followed by Technology and Financials.

Against the trend, Candriam SCA opened a new position in Tenable Holdings worth $16.3M.

  • Candriam SCA's largest Q2 2022 buy was Tenable Holdings: 359,981 shares worth $16.3M.
  • Candriam SCA added most to Procter & Gamble in Q2 2022, an estimated $38.7M increase.
  • Candriam SCA's biggest Q2 2022 reduction was Microsoft, cutting an estimated $65.7M.
  • Candriam SCA fully exited TriState Capital Holdings, Inc. in Q2 2022, selling an estimated $20.9M.
  • Candriam SCA's ten largest holdings make up 25% of its $12.1B portfolio in Q2 2022.
  • Candriam SCA opened 52 new positions and closed 83 in Q2 2022.
  • Candriam SCA's portfolio value fell 17% quarter-over-quarter to $12.1B.

Based on Candriam SCA's 13F filing for Q2 2022, filed 3 Aug 2022.